Hayward Marshall A. 4

What Happened
Marshall A. Hayward, Chief Scientific Officer and director of Jupiter Neurosciences (JUNS), was awarded 259,231 stock options on June 2, 2026. The Form 4 reports the acquisition as a derivative award with a reported transaction amount of $0.00. This was an option grant (award), not an open‑market purchase or sale, so there was no cash exchanged at grant.

Key Details

• Transaction date: 2026-06-02 (Form 4 filed 2026-06-04; filing appears timely).
• Transaction type/code: Award/Grant (A) — 259,231 options reported.
• Price reported on Form 4: $0.00 (derivative award entry).
• Shares/ownership after transaction: not specified in the provided summary of the filing.
• Footnote: The 259,231 options were granted under the issuer’s 2025 Equity Incentive Plan as a discretionary bonus for services during fiscal 2025. Options vest over three years beginning September 2, 2026, in equal quarterly installments, subject to continued employment through each vesting date.

Context
This is a compensation-related option grant. Options are derivatives that generally must vest and then be exercised (possibly for a cash exercise price) before converting to stock; the grant itself does not represent immediately tradable shares. Such awards are common for executives and do not by themselves indicate a buy or sell signal.